A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients

Acta Oncologica

Volumn 47, Issue 4, 2008, Pages 600-607

  Alsner, Jan ^a   Jensen, Vibeke ^a   Kyndi, Marianne ^a   Vrou Offersen, Birgitte ^a   Vu, Phuong ^b   Børresen Dale, Anne Lise ^b,c   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; ZINC; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DNA BINDING; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENE SEQUENCE; HEALTH CARE ORGANIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; STAINING; TISSUE SECTION; TP53 GENE; TUMOR CELL; BREAST TUMOR; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION, MISSENSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45149089389     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802047411     Document Type: Article

References (18)

1. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-67.
2. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 1996;2:2007-13.
3. Petitjean A, Achatz MI, Børresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65.
4. Soussi T. p53 alterations in human cancer: More questions than answers. Oncogene 2007;26:2145-56.
5. Offersen BV, Alsner J, Olsen KE, Riisbro R, Brünner N, Sørensen FB, et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008;47:618-32.
6. Offersen BV, Sørensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer-relevance to prognosis. Acta Oncol 2002;41:695-703.
7. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641-8.
8. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
9. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247-53.
10. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:2268-75.
11. Hansen LL, Andersen J, Overgaard J, Kruse TA. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 1998;106:371-7.
12. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000;6:3923-31.
13. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, et al. Tissue microarrays compared with whole sections and biochemical analyses: A subgroup analysis of DBCG82 b&c. Acta Oncol 2008;47:591-99.
14. Kyndi M, Sørensen FB, Knudsen H, Alsner J, Overgaard M, Nielsen HM, et al. Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. Acta Oncol 2008;47:608-17.
15. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 2007;12:303-12.
16. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: The effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69:26-31.
17. Battifora H. p53 immunohistochemistry: A word of caution. Hum Pathol 1994;25:435-7.
18. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-82.